Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
27 Junho 2023 - 1:01PM
Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a
commercial-stage biopharmaceutical company focused on the
development and commercialization of novel therapies for
life-threatening diseases and other public health threats, today
acknowledged receipt of a letter from NexPoint Asset Management,
L.P., together with its affiliates (collectively, "NexPoint").
Paratek appreciates receiving constructive feedback from its
stockholders and as such, has actively engaged with NexPoint over
the past several months. However, Paratek’s board of directors
respectfully disagrees with NexPoint’s characterizations contained
in its letter.
Paratek looks forward to providing stockholders with additional
details with respect to the previously announced acquisition of
Paratek by Gurnet Point Capital and Novo Holdings A/S when it files
its proxy materials with the Securities and Exchange
Commission.
About Paratek Pharmaceuticals, Inc.Paratek
Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical
company focused on the development and commercialization of novel
therapies for life-threatening diseases and other public health
threats. The company's lead commercial product, NUZYRA®
(omadacycline), is a once-daily oral and intravenous antibiotic
available in the United States for the treatment of adults with
community-acquired bacterial pneumonia (CABP) and acute bacterial
skin and skin structure infections (ABSSSI).
Paratek is also conducting a Phase 2b study with NUZYRA in a
rare disease, nontuberculous mycobacterial (NTM) pulmonary disease,
caused by Mycobacterium abscessus complex.
In 2019, Paratek was awarded a contract from the U.S. Department
of Health and Human Services' Biomedical Advanced Research and
Development Authority (BARDA), now valued at up to $304 million, to
support the development and U.S.-based manufacturing of NUZYRA for
pulmonary anthrax.
For more information, visit www.ParatekPharma.com or
follow us on LinkedIn and Twitter.
Additional Information and Where to Find ItThis
communication may be deemed solicitation material in respect of the
proposed acquisition of Paratek Pharmaceuticals, Inc. (the
“Company”) by Resistance Merger Sub, Inc. (“Merger Sub”). This
communication does not constitute a solicitation of any vote or
approval. In connection with the proposed transaction, the
Company plans to file with the U.S. Securities and Exchange
Commission (the “SEC”) and mail or otherwise provide to its
stockholders a proxy statement regarding the proposed
transaction (the “Proxy Statement”), and the Company and
affiliates of the Company intend to jointly file a transaction
statement on Schedule 13e-3 (the “Schedule 13e-3”). The Company may
also file other documents with the SEC regarding the proposed
transaction (the “Proxy Statement”), and the Company and affiliates
of the Company intend to jointly file a transaction statement on
Schedule 13e-3 (the “Schedule 13e-3”). The Company may also file
other documents with the SEC regarding the proposed transaction.
This document is not a substitute for the proxy statement or any
other document that may be filed by the Company with the SEC.
BEFORE MAKING ANY VOTING DECISION, THE COMPANY'S
STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT AND THE SCHEDULE
13E-3 IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AND ANY
OTHER DOCUMENTS FILED BY THE COMPANY WITH THE SEC IN CONNECTION
WITH THE PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE THEREIN
BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE
PROPOSED TRANSACTION BECAUSE THEY CONTAIN IMPORTANT INFORMATION
ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED
TRANSACTION.
Any vote in respect of resolutions to be proposed at a
stockholder meeting of the Company to approve the proposed
transaction or related matters, or other responses in relation to
the proposed transaction, should be made only on the basis of the
information contained in the Proxy Statement. Stockholders may
obtain a free copy of the Proxy Statement, the Schedule 13e-3 and
other documents the Company files with the SEC (when available)
through the website maintained by the SEC at www.sec.gov. The
Company makes available free of charge on its investor relations
website at www.paratekpharma.com/investor-relations copies of
materials it files with, or furnishes to, the SEC.
The proposed transaction will be implemented solely pursuant to
the Agreement and Plan of Merger, dated as of June 6, 2023, among
the Company, Merger Sub and Resistance Acquisition, Inc., which
contains the full terms and conditions of the proposed
transaction.
Participants in the SolicitationThe Company and
certain of its directors, executive officers and certain employees
and other persons may be deemed to be participants in the
solicitation of proxies from the Company’s stockholders in
connection with the proposed transaction. Security holders may
obtain information regarding the names, affiliations and interests
of the Company’s directors and executive officers in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31,
2022, which was filed with the SEC on March 16, 2023. To the extent
the holdings of the Company’s securities by the Company’s
directors and executive officers have changed since the amounts set
forth in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2022, such changes have been or will be
reflected on Statements of Change in Ownership on Form 4 filed with
the SEC. Investors may obtain additional information regarding the
interests of participants in the solicitation of proxies from the
Company’s stockholders in connection with in the proposed
transaction, which may, in some cases, be different than those of
the Company’s stockholders generally, by reading the proxy
statement relating to the proposed transaction when it is filed
with the SEC and other materials that may be filed with the SEC in
connection with the proposed transaction when they become
available. These documents (when available) may be obtained free of
charge from the SEC’s website at www.sec.gov and the investor
relations page of the Company’s website at
www.paratekpharma.com/investor-relations.
CONTACTS:For Investors:PJ
Kelleher LifeSci
Advisorspkelleher@lifesciadvisers.com617-430-7579
For Media:Christine FanelleScient
PRChristine@ScientPR.com215-595-5211
Paratek Pharmaceuticals (NASDAQ:PRTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024